Axsome Therapeutics, Inc. (AXSM)
207.00
+1.52
(+0.74%)
USD |
NASDAQ |
Aug 26, 16:00
207.00
0.00 (0.00%)
After-Hours: 20:00
Axsome Therapeutics Enterprise Value : 10.65B for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 10.65B |
| August 24, 2026 | 10.65B |
| August 21, 2026 | 10.77B |
| August 20, 2026 | 10.78B |
| August 19, 2026 | 11.32B |
| August 18, 2026 | 11.19B |
| August 17, 2026 | 11.22B |
| August 14, 2026 | 11.08B |
| August 13, 2026 | 11.08B |
| August 12, 2026 | 11.13B |
| August 11, 2026 | 11.19B |
| August 10, 2026 | 11.46B |
| August 07, 2026 | 11.03B |
| August 06, 2026 | 10.89B |
| August 05, 2026 | 11.04B |
| August 04, 2026 | 11.00B |
| August 03, 2026 | 10.94B |
| July 31, 2026 | 11.31B |
| July 30, 2026 | 12.18B |
| July 29, 2026 | 11.80B |
| July 28, 2026 | 12.15B |
| July 27, 2026 | 12.37B |
| July 24, 2026 | 12.51B |
| July 23, 2026 | 12.54B |
| July 22, 2026 | 12.44B |
| Date | Value |
|---|---|
| July 21, 2026 | 12.30B |
| July 20, 2026 | 11.50B |
| July 17, 2026 | 11.93B |
| July 16, 2026 | 12.30B |
| July 15, 2026 | 12.33B |
| July 14, 2026 | 12.21B |
| July 13, 2026 | 11.84B |
| July 10, 2026 | 12.13B |
| July 09, 2026 | 12.92B |
| July 08, 2026 | 12.75B |
| July 07, 2026 | 12.97B |
| July 06, 2026 | 12.59B |
| July 02, 2026 | 12.68B |
| July 01, 2026 | 12.49B |
| June 30, 2026 | 12.71B |
| June 29, 2026 | 12.31B |
| June 26, 2026 | 12.34B |
| June 25, 2026 | 12.12B |
| June 24, 2026 | 12.15B |
| June 23, 2026 | 12.36B |
| June 22, 2026 | 12.66B |
| June 18, 2026 | 12.80B |
| June 17, 2026 | 12.88B |
| June 16, 2026 | 12.87B |
| June 15, 2026 | 12.94B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.207T |
| Liquidia Corp. | 6.179B |
| Filana Therapeutics, Inc. | -36.85M |
| CorMedix, Inc. | 552.63M |
| Eloxx Pharmaceuticals, Inc. | 15.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -51.31M |
| Revenue (Quarterly) | 218.38M |
| Total Expenses (Quarterly) | 269.69M |
| EPS Diluted (Quarterly) | -0.9906 |
| Gross Profit Margin (Quarterly) | 92.47% |
| Profit Margin (Quarterly) | -23.50% |
| Earnings Yield | -1.82% |
| Normalized Earnings Yield | -1.793 |